Leucid Bio

About

Leucid is progressing novel cart therapies that produce a better and more durable response.

London,England,United Kingdom
11 - 50
http://www.leucid.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: £11.50M
Industries: Biotechnology
Founded date: Jan 1, 2014
Number Of Employee: 11 - 50
Operating Status: Active

Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

1

£11.50M

Leucid Bio has raised a total of £11.50M in funding over 2 rounds. Their latest funding was raised on Oct 21, 2021 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Oct 21, 2021	Series A	£11.50M	5	Epidarex Capital Vulpes Investment Management Pte Ltd	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

5

Leucid Bio is funded by 5 investors. Epidarex Capital and Vulpes Investment Management Pte Ltd are the most recent investors.

Investor Name	Lead Investor	Funding Round
Epidarex Capital	Yes	Series A
Vulpes Investment Management Pte Ltd	Yes	Series A
2invest	—	Series A
British Business Bank	—	Series A
Sofinnova Partners	—	Series A